Trace Amine-Associated Receptor (TAAR) Modulator Therapy targets a family of G-protein coupled receptors (GPCRs) that respond to trace amines—biogenic amines present in the brain at low concentrations. The TAAR family includes five members in humans: TAAR1, TAAR5, TAAR6, TAAR8, and TAAR9, each with distinct expression patterns and pharmacological profiles [1][2]. These receptors represent emerging therapeutic targets for neurodegenerative diseases due to their modulatory effects on monoaminergic neurotransmission—specifically dopamine, serotonin, and noradrenaline signaling pathways that are fundamentally disrupted in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease [3][4].
The TAAR family receptors signal through distinct G-protein pathways:
| Receptor | G-protein Coupling | Endogenous Ligands | Therapeutic Target |
|---|---|---|---|
| TAAR1 | Gs/Gi | β-PEA, tyramine, octopamine | Dopamine modulation |
| TAAR5 | Gi/o | Trimethylamine (TMA) | Olfactory function |
| TAAR6 | Gi/o | Unknown | Serotonergic modulation |
| TAAR8 | Gi/o | Unknown | Noradrenergic modulation |
| TAAR9 | Gi/o | Unknown | Mixed monoamine effects |
| Compound | Stage | Indication | Mechanism |
|---|---|---|---|
| RO5263397 | Preclinical | AD/PD | Selective TAAR1 agonist |
| RO5172990 | Preclinical | Depression/PD | TAAR1 partial agonist |
| SEP-363856 | Phase II | Schizophrenia | TAAR1 agonist, D2 antagonist |
| Ulotaront | Phase III | Schizophrenia | TAAR1/5-HT1A agonist |